The closing of the Cullgen acquisition is a transformative event that creates a fully integrated biopharma with both commercial revenue (ETUARY in China) and a novel TPD/DAC pipeline. The key near-term catalyst is the June 10, 2026 stockholder vote on the conversion of Series B Preferred Stock — approval is necessary to unlock full conversion and avoid overhang. Monitor for the filing of pro forma financials and Cullgen's historical financials, which will provide clarity on the combined entity's revenue base and R&D spending.
Price Chart
Executive Summary
Gyre Therapeutics closed its all-stock acquisition of Cullgen Inc. on May 4, 2026, in a transaction valued at approximately $300 million. Cullgen becomes a wholly owned subsidiary, and the combined entity gains a commercial-stage product (ETUARY) in China and a pipeline of targeted protein degraders. The filing also details the issuance of Series B Convertible Preferred Stock, board and officer changes (new CEO/CFO), and assumption of Cullgen's stock incentive plan.
Key Facts
- Acquisition of Cullgen closed on May 4, 2026, in an all-stock transaction valued at approximately $300 million.
- Cullgen becomes a wholly owned subsidiary; combined entity has a commercial-stage product (ETUARY) in China and a pipeline of targeted protein degraders (TPDs) and degrader-antibody conjugates (DACs).
- Ying Luo, Ph.D., appointed CEO and President; Thomas Eastling appointed CFO.
- Series B Convertible Preferred Stock issued to certain Cullgen holders; conversion into common stock requires stockholder approval at June 10, 2026 annual meeting.
- Cullgen's 2018 Stock Incentive Plan assumed and amended; 4,156,800 shares authorized under the plan, but no new awards may be granted after May 4, 2026.
- Merger treated as a combination of entities under common control (both Gyre and Cullgen controlled by GNI Group Ltd.); financial statements to be retrospectively adjusted.
Financial Impact
All-stock transaction valued at approximately $300 million. No cash consideration; dilution from issuance of Series B Preferred Stock and common stock to Cullgen holders. Conversion of Preferred Stock capped at 19.99% of outstanding common stock prior to stockholder approval.
Risk Factors
- Stockholder approval of Series B Preferred Stock conversion is required; failure could create capital structure uncertainty and limit conversion.
- Integration risk: combining U.S. and China operations, especially given the common control structure and retrospective accounting adjustments.
- Dilution risk: issuance of shares to Cullgen holders and potential conversion of Preferred Stock could dilute existing shareholders.
- Clinical and regulatory risk: F351 NDA under priority review in China; ETUARY Phase 3 trials for pneumoconiosis and RILI are ongoing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (GYRE) — Batch item 1 | 0001140361-26-018716 |
| Document: ef20072211_8k.htm | 0001140361-26-018717 |
| Document: ef20072211_ex99-1.htm | 0001140361-26-018716 |
| Document: 0001140361-26-018716-index-headers.html | 0001140361-26-018716 |
| Document: 0001140361-26-018716-index.html | 0001140361-26-018716 |
| Document: 0001140361-26-018716.txt | 0001140361-26-018716 |
| DEFA14A Filing (GYRE) — Batch item 7 | 0001140361-26-018717 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $5.85 | awaiting T+20 | — | $5.85 (−0.00%) |
Sep 1, 2026 7w ago | 8-K | $6.47 $7.35 | ▲ +13.52% | ▲ +12.34% | $5.85 (−9.58%) |
Aug 26, 2026 8w ago | 8-K | $6.65 $7.43 | ▲ +11.73% | ▲ +10.53% | $5.85 (−12.03%) |
Aug 7, 2026 11w ago | 8-K | $6.67 $6.86 | ▼ −2.85% | ▼ −3.25% | $5.85 (+12.29%) |
Aug 4, 2026 11w ago | EFFECT | $6.15 $6.47 | ▲ +5.20% | ▲ +6.44% | $5.85 (−4.88%) |
Jul 13, 2026 15w ago | S-3/A | $6.34 $6.64 | ▲ +4.73% | ▲ +2.24% | $5.85 (−7.73%) |
Jun 2, 2026 20w ago | 8-K | $5.56 $6.52 | ▲ +17.27% | ▲ +18.83% | $5.85 (+5.22%) |
May 14, 2026 23w ago | 8-K | $6.55 $5.86 | ▼ −10.53% | ▼ −12.65% | $5.85 (−10.69%) |
May 4, 2026 25w ago | 8-K / DEFA14A | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $5.85 (−26.14%) |
May 4, 2026 25w ago | Press Release | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $5.85 (−26.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers